1. Moore, Alyssa, Linden, Jérôme, Jentsch, James D. 2021. Syn3 Gene Knockout Negatively Impacts Aspects of Reversal Learning Performance. In eNeuro, 8, . doi:10.1523/ENEURO.0251-21.2021. https://pubmed.ncbi.nlm.nih.gov/34413083/
2. Nagabhushan, T L, Maneval, D C, Benedict, W F, Engler, H, Connor, R J. 2007. Enhancement of intravesical delivery with Syn3 potentiates interferon-alpha2b gene therapy for superficial bladder cancer. In Cytokine & growth factor reviews, 18, 389-94. doi:. https://pubmed.ncbi.nlm.nih.gov/17692556/
3. Yamashita, Motoyuki, Rosser, Charles J, Zhou, Jain-Hua, Dinney, Colin P N, Benedict, William F. . Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. In Cancer gene therapy, 9, 687-91. doi:. https://pubmed.ncbi.nlm.nih.gov/12136430/
4. Martini, Alberto, Tholomier, Côme, Mokkapati, Sharada, Dinney, Colin P N. 2023. Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval. In Frontiers in immunology, 14, 1260498. doi:10.3389/fimmu.2023.1260498. https://pubmed.ncbi.nlm.nih.gov/37705979/
5. Herzog, Roland W, Suzuki, Masataka. . Adenoviral gene therapy for bladder cancer. In Cell, 186, 893. doi:10.1016/j.cell.2023.02.009. https://pubmed.ncbi.nlm.nih.gov/36868210/
6. Yuan, Li, Yang, Xiaohui, Auman, Dirk, Makaroff, Christopher A. 2013. Expression of epitope-tagged SYN3 cohesin proteins can disrupt meiosis in Arabidopsis. In Journal of genetics and genomics = Yi chuan xue bao, 41, 153-64. doi:10.1016/j.jgg.2013.11.006. https://pubmed.ncbi.nlm.nih.gov/24656235/
7. Dinney, Colin P N, Fisher, Mark B, Navai, Neema, Wszolek, Matthew F, Benedict, William F. 2013. Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. In The Journal of urology, 190, 850-6. doi:10.1016/j.juro.2013.03.030. https://pubmed.ncbi.nlm.nih.gov/23507396/
智鼠故事 
